CONTACTS 

SUBJECTS
Meeting Doctor Examine Response to Chemotherapy Treatments Taxol Xel

0403 -
0403 -    ..
0404 - Summary/Objective
0405 -
040501 - Follow up ref SDS 98 0000, ref SDS 91 0000.
040502 -
040503 - Miraculous recovery after three (3) cycles of treatment with Taxotere
040504 - and capecitabine (Xeloda), CA 15-3 continues decline, ref SDS 0 GJ5M,
040505 - and CT test shows no evidence of distant metastasis, with prior
040506 - swelled lymph nodes at right axillary almost totally resolved to
040507 - subcentimeter level. ref SDS 0 B58M  Clinical examination of left
040508 - breast shows near normal coloration and texture, indicating IBC nearly
040509 - healed. ref SDS 0 025H  Doctor describes "window of opportunity" to
040510 - perform a masectomy; schedules follow up examination in surgery
040511 - department. ref SDS 0 XQ41  Analysis of criteria for surgery is
040512 - pending. ref SDS 0 2J72  Treatment was continued at current dosage for
040513 - the fourth (4th) treatment of Taxotere and capecitabine (Xeloda),
040514 - ref SDS 0 AW5G, based on diary of patient history showing side effects
040515 - are tolerable. ref SDS 0 NT3I  Prescription for bladder infection was
040516 - successful using Keflex. ref SDS 0 VT3O
040517 -
040518 -
040519 -
040520 -
040522 -  ..
0406 -
0407 -
0408 - Progress
0409 -
040901 - Agenda for Work Plan After Switching to Taxotere and Capecitabine
040902 -
040903 - Follow up ref SDS 98 SM6M, ref SDS 91 SM6M.
040904 -
040905 - This is the 3rd review after changing treatment to Taxotere and
040906 - capecitabine (Xeloda) initiated on 050329, ref SDS 80 T58M, and
040907 - starting on 050415, ref SDS 84 0001, and occurs at the end of the 2nd
040908 - week of the 3rd cycle on 050527, ref SDS A3 0001, beginning the week
040909 - with no treatment, prior to starting cycle 4.
040911 -  ..
040912 - Millie created an agenda on the marking board...
040913 -
040914 -        CA 15-3 dramatic fall...................... ref SDS 0 GJ5M
040915 -        CT test report............................. ref SDS 0 NL4N
040916 -        Breast exam recovering IBC................. ref SDS 0 025H
040917 -        Surgeon report on masectomy................ ref SDS 0 XQ41
040918 -        Treatment plan............................. ref SDS 0 AW5G
040919 -        Side Effects adjust dosage................. ref SDS 0 NT3I
040920 -        Bladder infection.......................... ref SDS 0 VT3O
040921 -        Dental cleaning............................ ref SDS 0 YU8N
040922 -
040923 -
040924 -
040925 -
040926 -
040927 -
0410 -

SUBJECTS
CA 15-3 56 Fall from 67 Shows Favorable Response to Treatment with T

1203 -
120401 -  ..
120402 - CA 15-3 Cancer Marker 56 Fall from 67
120403 -
120404 - Follow up ref SDS 98 087J, ref SDS 91 087J.
120405 -
120406 - Blood test on 050527 shows CA 15-3 dropped to 56 from 67 the prior
120407 - test on 050512, reported during the meeting on 050520. ref SDS 98 087J
120409 -           ..
120410 -          050527......... 56 H............. 050610, ref SDS 0 087J
120411 -          050512......... 67 H............. 050520, ref SDS 98 087J
120412 -          050506......... 80 H............. 050520, ref SDS 98 087J
120413 -          050415.........105 H............. 050422, ref SDS 91 087J
120414 -          050325.........100 H............. 050329, ref SDS 80 087J
120415 -          050318.........101 H............. 050325, ref SDS 78 2N5J
120416 -          050304......... 88 H............. 050311, ref SDS 72 087J
120417 -          050225......... 95 H............. 050308, ref SDS 71 0001
120418 -          050211......... 78 H............. 050214, ref SDS 69 02BB
120419 -          050128......... 67 H............. 050204, ref SDS 67 087J
120420 -          041228......... 56 H............. 041230, ref SDS 62 087J
120421 -          041204......... 43 H............. 041210, ref SDS 59 087J
120422 -          041007......... 39............... 041104, ref SDS 50 087J
120423 -          040923......... 49 H............. 041005, ref SDS 46 087J
120424 -          040908......... 44 H............. 040909, ref SDS 45 087J
120425 -          040825......... 47 H............. 040812, ref SDS 45 087J
120426 -          040811......... 42 H............. 040812, ref SDS 44 087J
120427 -          040728......... 43 H............. 040729, ref SDS 42 2N5J
120428 -          040712......... 47 H............. 040713, ref SDS 41 087J
120429 -          040614......... 55 H............. 040615, ref SDS 40 PX6X
120430 -          040517......... 78 H............. 040601, ref SDS 39 2N5J
120431 -          040311......... 70 H............. 040318, ref SDS 34 SM6M
120432 -          040205......... 60 H............. 040211, ref SDS 33 SM6M
120433 -          031201......... 62 H............. 031205, ref SDS 32 SM6M
120434 -          030912......... 66 H............. 030915, ref SDS 31 SM6M
120435 -          030708......... 68 H............. 030710, ref SDS 30 SM6M
120436 -          030503......... 54 H............. 030508, ref SDS 28 SM6M
120437 -          030403......... 45 H............. 030508, ref SDS 28 SM6M
120438 -          030215......... 46 H............. 030220, ref SDS 27 5E6L
120439 -          030106......... 37 H............. 030109, ref SDS 26 SM6M
120440 -          021202......... 41 H?............ 021204, ref SDS 25 SP5G
120441 -          021111......... 36 H?............ 021113, ref SDS 24 Y65I
120442 -          021023......... 33 H?............ 021023, ref SDS 23 SQ5I
120443 -          020930......... 33 H?..29........ 021002, ref SDS 22 SQ5I
120444 -          020917......... 36 H?............ 020924, ref SDS 21 SQ5I
120445 -          020717......... 59 H?............ 020726, ref SDS 20 YN5K
120446 -          020629......... 75 H ............ 020705, ref SDS 18 UX6I
120447 -          020608........  67 H ............ 020614, ref SDS 17 0001
120448 -          020603........ 108 H ............ 020607, ref SDS 16 X67F
120449 -          020511........ 117 H ............ 020603, ref SDS 15 PJ4J
120450 -          020419......... 81 H ............ 020430, ref SDS 14 7N5H
120451 -          020321......... 85 H ............ 020405, ref SDS 13 6T8K
120452 -
120453 -
120455 -  ..
1205 -
1206 -
1207 - Analysis
1208 -
120801 - CA 15-3 56 Cancer Marker Continues Decline Under New Treatment
120802 -
120803 - Follow up ref SDS 98 GJ5M, ref SDS 91 GJ5M.
120804 -
120805 - Doctor cited continued favorable response to treatment with Taxotere
120806 - and capecitabine (Xeloda), falling dramatically from 105, since
120807 - changing treatments on 050415, ref SDS 84 407N, and even with
120808 - reduction of dosage for capecitabine (Xeloda) by 25%, ordered on
120809 - 050520, ref SDS 98 VP4N, and further recovery from IBC has occurred
120810 - while missing an entire week of treatment with capecitabine due to
120811 - severe side effects, reported on 050514. ref SDS 95 RU9M
120812 -
120813 -        [On 050617 completed 4th treatment; doctor schedules more
120814 -        treatments, and meeting with surgeon delayed 4 weeks to end of
120815 -        July; patient requests meeting on treatment plan. ref SDS A6
120816 -        407N
120818 -         ..
120819 -        [On 050708 CA 15-3 37 falls to lowest level ever. ref SDS A7
120820 -        2N5J
120822 -         ..
120823 -        [On 050729 CA 15-3 46 rises 25% from 37 reported on 050610; may
120824 -        align with regional metastasis in right axillary lymph nodes
120825 -        not totally resolved, reported on 050610, ref SDS 0 B58M, and
120826 -        subsequent rising growth. ref SDS A9 ST6G
120827 -
120828 -
120829 -
120830 -
120831 -
1209 -

SUBJECTS
CT Test 050530 Shows No Distant Matastasis by Size Criteria CT Test

1503 -
150401 -  ..
150402 - CT Test Shows Progress with New Protocol Taxotere Capecitabine Xeloda
150403 -
150404 - Follow up ref SDS 98 NL4N, ref SDS 91 NL4N.
150405 -
150406 - The doctor submitted pathology analysis for the CT test performed a
150407 - few weeks ago on 050530, which was ordered on 050520 to evaluate
150408 - compounding growth of cells under the right arm in the face of falling
150409 - CA 15-3 and reduced inflammation from IBC.
150411 -           ..
150412 -          Prior Tests...
150413 -
150414 -              Date               Received             Source
150415 -              050530 reported on 050610.............. ref SDS 0 G75L
150416 -              050325 reported on 050422.............. ref SDS 91 G75L
150417 -              041217 reported on 041230.............. ref SDS 62 G75L
150418 -              041103 reported on 041104.............. ref SDS 50 NL4N
150419 -              040921 reported on 041005.............. ref SDS 46 NL4N
150420 -              040710 reported on 040811.............. ref SDS 43 DU9I
150421 -              040410 reported on 040416.............. ref SDS 35 HX4K
150422 -              040307 reported on 040318.............. ref SDS 34 LK5L
150423 -              031031 reported on 031205.............. ref SDS 32 IG9K
150424 -              030626 reported on 030710.............. ref SDS 30 AL6N
150425 -              030428 reported on 030508.............. ref SDS 28 LK5L
150427 -  ..
150428 - CT test dated 050530 shows....
150429 -
150430 -       Patient
150437 -        ..
150438 -       68/F Radiology Report               Exam  1 of 1
150439 -       Page 1
150441 -        ..
150442 -       CT SCAN OF NECK, CHEST, Abdomen (digital)
150444 -        ..
150448 -        ..
150449 -       History
150450 -
150451 -         Breast cancer follow up
150453 -        ..
150454 -       Findings
150455 -
150456 -         Spiral CT of the neck, chest and abdomen was performed with
150457 -         the use oral and intravenous contrast.  Comparison is made to
150458 -         a prior study of 050325.
150460 -          ..
150461 -         In the neck there is no significant adenopathy or mass.
150463 -          ..
150464 -         In the chest, there are no pulmonary parenchymal masses.
150465 -         There is no significant mediastinal or hilar adenopathy.  The
150466 -         right axillary lymph node has much decreased in mass, now
150467 -         measuring approximately 1 cm.
150468 -
150469 -             [On 060126 mild FDG activity noted in the right axillary
150470 -             region which may represent a local inflammatory process,
150471 -             although metastatic disease cannot be entirely excluded.
150472 -             ref SDS B2 WA7J
150474 -          ..
150475 -         In the abdomen, again is noted a cyst in the dome of the
150476 -         liver.  The liver otherwise appears normal.  The spleen,
150477 -         pancreas, adrenals, gallbladder appear normal.  The kidneys
150478 -         show tiny cysts.  There is no significant adenopathy.
150480 -          ..
150481 -         In the pelvis there is no adenopathy, mass or fluid
150482 -         collection.
150484 -        ..
150485 -       Impression
150486 -
150487 -         Almost total resolution of the right axillary enlarged lymph
150488 -         node compared to the prior study.  No other significant
150489 -         findings.
150490 -
150491 -             [On 050729 CA 15-3 46 rises 25% from 37 reported on
150492 -             050610; may align with regional metastasis in right
150493 -             axillary lymph nodes not totally resolved, reported on
150494 -             050610, ref SDS 0 B58M, and subsequent rising growth.
150495 -             ref SDS A9 ST6G
150497 -              ..
150498 -             [On 060126 mild FDG activity noted in the right axillary
150499 -             region which may represent a local inflammatory process,
150500 -             although metastatic disease cannot be entirely excluded.
150501 -             ref SDS B2 WA7J
150503 -        ..
150504 -       DG Jung, MD
150506 -        ..
150507 -       DD:  050531    DT:  050601   SJE
150508 -
150509 -
150510 -
150511 -
1506 -

SUBJECTS
Auxillary Right Lymph Nodes CT Test 050530 Shows No Distant Matastasi    4

2403 -
240401 -  ..
240402 - CT Testing Shows No Evidence Distant Metastasis for 4 Years
240403 - Lymph Nodes Right Auxillary Subside to Less that 1 CM Almost Resolved
240404 - Right Auxillary Almost Resolved Lymph Nodes Subside to Less that 1 CM
240405 -
240406 - Follow up ref SDS 98 B58M, ref SDS 91 B58M.
240407 -
240408 - Doctor noted that the CT test on 050530 indicates that prior
240409 - accelerating growth under the right arm has stopped, and lymph nodes
240410 - have shrunk from 18 mm x 20 mm for the test on 050325, reported on
240411 - 050422, ref SDS 91 B58M, to now less than 10 mm (1 CM), ref SDS 0 TH9N
240413 -  ..
240414 - The doctor further cited the impression that this issue is nearly
240415 - totally resolved. ref SDS 0 WA52
240416 -
240417 -        [On 050729 CA 15-3 46 rises 25% from 37 reported on 050610; may
240418 -        align with regional metastasis in right axillary lymph nodes
240419 -        not totally resolved, reported on 050610, ref SDS 0 B58M, and
240420 -        subsequent rising growth. ref SDS A9 ST6G
240422 -         ..
240423 -        [On 050729 doctor maintains chemotherapy treatment for two (2)
240424 -        more cycles to avoid prior relapse. ref SDS A9 VP4N
240426 -         ..
240427 -        [On 051007 PET scan test does not discuss finding of CT test on
240428 -        050530 reported today, but impliedly resolves all pending
240429 -        matters; need confirmation of comparison with CT test on
240430 -        050530. ref SDS B1 5D9J
240432 -  ..
240433 - The doctor indicated that CT testing, listed above, ref SDS 0 XU7N,
240434 - shows no evidence of distant metastasis flowing from cancer in the
240435 - left breast, except for swelled lymph nodes on the left side under the
240436 - arm and on the neck, which are symptoms of IBC, reported in research
240437 - on 040517. ref SDS 38 LS3L  This analysis today aligns with prior
240438 - review during the meeting on 040713, ref SDS 41 NK9H, and discussed
240439 - again during the meeting a month later on 040812. ref SDS 44 8R6M
240440 -
240441 -
240442 -
240443 -
2405 -

SUBJECTS
Auxillary Right Left No Clinical Examination for Lumps CT Test 05053

2803 -
280401 -  ..
280402 - Lumps Under Arms No Clinical Examination No Problems Reported
280403 -
280404 - Follow up ref SDS 98 MW8J, ref SDS 91 MW8J.
280405 -
280406 - There was no examination of left and right axillary, based on CT test
280407 - reporting previously swelled lymph nodes under right arm are almost
280408 - total resolved and are now subcentimeter. ref SDS 0 B58M
280409 -
280410 -
280411 -
280412 -
2805 -

SUBJECTS
Neck Lumps No Evidence Left and Right Side Doctor Clinical Examinati
Neck Lumps Lymph Nodes Left Side No Examination Patient Reports Favo

3404 -
340501 -  ..
340502 - Lumps in Neck No Evidence of Swelling Indicating Cancer Receded
340503 -
340504 - Follow up ref SDS 98 8R6M, ref SDS 91 8R6M.
340505 -
340506 - No examination of the neck.
340507 -
340508 -
340509 -
340510 -
340511 -
3406 -

SUBJECTS
Wound Biopsy Left Breast Nearly Healed after 3 Treatment Taxotere Ca

4103 -
410401 -  ..
410402 - Wound Biopsy Continues Healing with Treatment Taxotere Capecitabine
410403 -
410404 - Follow up ref SDS 98 6T5G, ref SDS 91 6T5G.
410405 -
410406 - The doctor examined the left breast and observed fully healed biopsy
410407 - wound following the 3rd cycle treatment of chemotherapy for IBC with
410408 - Taxotere and capecitabine (Xeloda) beginning on 050415. ref SDS 84
410409 - 0001
410410 -
410411 -     [On 050727 followed up examination by surgeon shows biopsy wound
410412 -     fully healed after 4 treatments with Taxotere and capecitabine.
410413 -     ref SDS A8 WI6K
410414 -
410415 -
410416 -
410417 -
410418 -
4105 -

SUBJECTS
Breast Examination IBC Nearly Healed Recovery Inflammation Greatly R

4603 -
460401 -  ..
460402 - IBC Improvement Continues Inflammation Nearly Entirely Eliminated
460403 - Redness IBC Nearly Eliminated Almost Fully Healed Blisters Sores Gone
460404 - Blistering Sores Cancer Left Breast IBC Fully Subsided and Healed
460405 - Taxotere Capecitabine Xeloda Significant Improvement Treating IBC
460406 -
460407 - Follow up ref SDS 98 025H, ref SDS 91 025H.
460408 -
460409 - Doctor very pleased with examination of the left breast showing
460410 - substantial healing and recovery from IBC, based on near normal
460411 - coloration, and softening of skin compared with right breast and after
460412 - three (3) treatments with Taxotere and capecitabine (Xeloda),
460413 - beginning on 050415, ref SDS 84 407N, and changing the treatment plan
460414 - on 050329, ref SDS 80 T58M, and, also, after reducing dosage of
460415 - capecitabine by 25% on 050520 to reduce side effects. ref SDS 98 V43H
460417 -  ..
460418 - This examination reflects CT test report today indicating regional
460419 - cancer in axillary, and supraclavicular sites, previously reported on
460420 - 040318, ref SDS 0 B58M, are resolved. ref SDS 0 B58M
460421 -
460422 -     [On 050729 Vivian, the pharmacist, explained strategy to start
460423 -     patients with maximum strength of capecitabine (Xeloda), then
460424 -     experiment to reduce the dose down to a level patients can
460425 -     tolerate. ref SDS A0 407N
460426 -
460427 -
460428 -
460429 -
460430 -
4605 -

SUBJECTS
Surgery Examination 1st Week July Evaluate Readiness for Masectomy P

5003 -
500401 -  ..
500402 - Widow of Opportunity Surgery for Local Control Avoid Relapse
500403 - Examination on Criteria for Masectomy During Window of Opportunity
500404 -
500405 - Follow up ref SDS 98 XQ41, ref SDS 91 XQ41.
500406 -
500407 - The doctor indicated that CT tests showing no distant disease, and
500408 - resolution of regional involvement, ref SDS 0 B58M, along with
500409 - significant improvement in the left breast recovering from IBC after
500410 - three (3) treatments with Taxotere and capecitabine (Xeloda), per
500411 - above, ref SDS 0 025H, present a "window of opportunity" for local
500412 - control with surgery to perform a masectomy after the 4th cycle of
500413 - treatments in about 3 weeks.  This will help prevent relapse by
500414 - treating "pockets of resistance" to cancer in the left breast, cited
500415 - on 050311, ref SDS 72 PA4N, to implement the treatment plan on 041230.
500416 - ref SDS 62 O48I
500417 -
500418 -     [On 051007 PET scan test confirms all prior findings of disease
500419 -     have been resolved. ref SDS B1 GJ4S
500421 -  ..
500422 - The doctor called and talked to the surgeon.  He explained planning
500423 - for a masectomy to help local control of disease and that examination
500424 - today shows dramatic recovery from IBC. ref SDS 0 025H  The doctor
500425 - requested another examination by the Surgery Department to follow up
500426 - prior work on 050324, when the surgeon wanted to see more improvement
500427 - in clearing IBC from the breast. ref SDS 76 WH5L  The doctor advised
500428 - the surgeon during the call that significant recovery has now been
500429 - achieved, and so justifies further consideration of surgery.
500430 -
500431 -     [On 051007 primary care physician presents purpose of standard
500432 -     mastectomy is for palliation in the event of future relapse.
500433 -     ref SDS B1 6A4N
500435 -  ..
500436 - The doctor asked if a meeting can be scheduled for next week to take
500437 - advantage of the current "window of opportunity" for surgery, created
500438 - by favorable response to treatments, per findings above? ref SDS 0
500439 - 025H
500441 -  ..
500442 - The surgeon has plans for a vacation the next few weeks, and so can
500443 - see Millie after returning from vacation the first week of July.
500445 -  ..
500446 - The doctor agreed; and the surgeon explained that Millie will receive
500447 - notice of a meeting for the first week in July, following the 4th
500448 - cycle of chemotherapy treatment with Taxotere and capecitabine
500449 - (Xeloda) currently scheduled for 050617.
500450 -
500451 -     [On 050617 completed 4th treatment; doctor schedules more
500452 -     treatments, and meeting with surgeon delayed 4 weeks to end of
500453 -     July; patient requests meeting to expedite treatment plan.
500454 -     ref SDS A6 407N
500456 -      ..
500457 -     [On 050727 follow up examination by surgeon shows biopsy wound
500458 -     fully healed, ref SDS A8 WI6K, and the entire breast has recovered
500459 -     sufficiently from IBC symptoms after 5 treatments with Taxotere
500460 -     and capecitabine for surgery to perform a masectomy. ref SDS A8
500461 -     YY7F
500463 -      ..
500464 -     [On 050729 doctor asks about results of meeting with the surgeon
500465 -     on 050727; pleased to hear from the patient understandings that
500466 -     the surgeon indicated IBC has recovered sufficiently for surgery
500467 -     to perform a masectomy. ref SDS A9 XQ41
500469 -  ..
500470 - There was no discussion today of criteria for surgery discussed by the
500471 - patient and the surgeon on 050324, ref SDS 76 OV5H, and requested by
500472 - the doctor during a meeting with the patient on 050329. ref SDS 80
500473 - T88I
500475 -  ..
500476 - There was no discussion today of criteria for patient to approve
500477 - surgery based on chances for extending quality of life, also, listed
500478 - in the record on 050324. ref SDS 76 VL4O
500480 -  ..
500481 - Previously, on 040517 research indicated that surgery can be effective
500482 - when IBC has not spread beyond the breast, and further cautions that
500483 - masectomy can increase chances for cancer to recur. ref SDS 38 YM3M
500484 - On 041117 received opinion from Doctor Benz at UCSF who stated that
500485 - surgery is not an option for Millie. ref SDS 51 OU5V  An opinion from
500486 - Doctor Guardino at Stanford indicated there might be a role for
500487 - surgery, if and when regression of inflammation occurs, reported on
500488 - 041209. ref SDS 57 SN97
500489 -
500490 -
500491 -
500492 -
500493 -
500494 -
5005 -

SUBJECTS
Taxotere Capeticabine (Xeloda) Chemotherapy Effectiveness Treatment

5403 -
540401 -  ..
540402 - Treatment Plan Chemotherapy Taxotere Capecitabine Continued
540403 - Taxotere Capecitabine (Xeloda) Chemotherapy Treatment Plan Continued
540404 -
540405 - Follow up ref SDS 98 AW5G, ref SDS 91 AW5G.
540406 -
540407 - After three (3) cycles of new treatments, and showing continued
540408 - improvement in patient recovery from IBC symptoms, per above,
540409 - ref SDS 0 025H, the doctor proposed completing the 4th cycle with...
540411 -         ..
540412 -    a.  Taxotere and capecitabine (Xeloda) couplet to implement the
540413 -        work plan on 041230, ref SDS 62 D49F, and modified on 050329 to
540414 -        schedule four (4) cycles of treatment, ref SDS 80 FP57, based
540415 -        on the 2nd opinion received from Doctor Benz on 041117.
540416 -        ref SDS 51 OU6S
540417 -
540418 -            [On 050617 completed 4th treatment; doctor schedules more
540419 -            treatments, and meeting with surgeon delayed 4 weeks to end
540420 -            of July; patient requests meeting on treatment plan.
540421 -            ref SDS A6 407N
540422 -
540423 -
540424 -
540425 -
540426 -
5405 -

SUBJECTS
Side Effects Decrease Tolerance Rises for Capecitabine (Xeloda) Dose

6403 -
640401 -         ..
640402 -    b.  Side Effects Tolerable Dose Xeloda (Capecitabine) Maintained
640403 -        Dose Treatments Maintained Side Effects Xeloda Now Tolerable
640404 -
640405 -        Follow up ref SDS 98 NT3I, ref SDS 91 NT3I.
640406 -
640407 -        The doctor explained side effects of Taxotere and capecitabine
640408 -        (Xeloda) on 050329, ref SDS 80 NT3I; on 050415 the pharmacist
640409 -        submitted documents detailing side effects. ref SDS 84 7F8Q  On
640410 -        050516 considerations for reducing the potency of capecitabine
640411 -        (Xeloda) were developed. ref SDS 96 BD4G
640413 -         ..
640414 -        The doctor asked about patient history from Millie's diary
640415 -        following Kaiser's instructions on 050415, ref SDS 84 XT5F,
640416 -        which the doctor used used on 050520 to adjust the dosage of
640417 -        capecitabine (Xeloda). ref SDS 98 VP3N
640419 -         ..
640420 -        Milled summarized side effects listed in the diary on 050422,
640421 -        since the last meeting on 050520.  Blistering of the feet and
640422 -        hands have not returned, and she has had more energy with
640423 -        several long hikes of over 3 miles. ref SDS 91 X59J
640425 -         ..
640426 -        The doctor maintained the dose for treatment with capecitabine
640427 -        (Xeloda) based on patient history showing tolerance for side
640428 -        effects and continuing positive benefits reported today.
640429 -        ref SDS 0 025H
640430 -
640431 -
640432 -
640433 -
640434 -
640435 -
6405 -

SUBJECTS
Trial Chemotherapy New Drug Treatment UCSF Millie Asks Primary Care

6703 -
670401 -         ..
670402 -    c.  Trial Chemotherapy New Drug Treatment UCSF
670403 -        New Drug Trial Chemotherapy Treatment UCSF
670404 -
670405 -        Follow up ref SDS 98 L27G.
670406 -
670407 -        There was no discussion of contacting UCSF about the
670408 -        announcement of a new trial, cited by Millie on 050520,
670409 -        ref SDS 98 L27G, by following up on the offer from Doctor Benz
670410 -        to collaborate on Millie's treatment, cited in a 2nd opinion
670411 -        received on 041117. ref SDS 51 OV3T
670412 -
670413 -
670414 -
670415 -
670416 -
670417 -
6705 -

SUBJECTS
Bladder Infection Treatment with Keflex Successful Prescription

7003 -
700401 -  ..
700402 - Bladder Infection Treatment with Keflex Successful Prescription
700403 - Urinary Tract Infection Prescribed Treatment with Keflex Effective
700404 -
700405 - Follow up ref SDS 98 VT3O.
700406 -
700407 - Millie reported that treatment prescribed on 050520 has been
700408 - successful treating bladder infection, reported in the record on
700409 - 050521 after taking prescribed Keflex, temperature dropped to 98.9;
700410 - so, Millie was able to take a trip to Colorado. ref SDS A1 6H6O
700411 -
700412 -
700413 -
700414 -
700415 -
7005 -

SUBJECTS
Dental Cleaning Scheduled for 050616 to Evaluate Infection and Treat
Dental Cleaning Important for Chemotherapy Patients to Detect Infect

7204 -
720501 -  ..
720502 - Dental Cleaning Important for Chemotherapy Patients
720503 -
720504 - Follow up ref SDS 98 YU8N.
720505 -
720506 - Millie reported schedule set on 050616 for dental examination and
720507 - cleaning to avoid infection, as planned during the meeting on 050520.
720508 - ref SDS 98 YU8N
720509 -
720510 -
720511 -
720512 -
720513 -
720514 -
720515 -
7206 -